Matthew Parris
Chief Tech/Sci/R&D Officer presso TRAWS PHARMA, INC.
Profilo
Matthew Parris is currently working as the Vice President-Clinical Operations at Traws Pharma, Inc. He previously worked as the Director-Clinical Operations at Aegerion Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc. He also held the position of Vice President-Clinical Development at Eleison Pharmaceuticals, Inc. Mr. Parris completed his undergraduate degree at Imperial College London.
Posizioni attive di Matthew Parris
Società | Posizione | Inizio |
---|---|---|
TRAWS PHARMA, INC. | Chief Tech/Sci/R&D Officer | 01/08/2018 |
Precedenti posizioni note di Matthew Parris
Società | Posizione | Fine |
---|---|---|
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Corporate Officer/Principal | - |
AEGERION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formazione di Matthew Parris
Imperial College London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 2 |
---|---|
TRAWS PHARMA, INC. | Health Technology |
INOVIO PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 2 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Eleison Pharmaceuticals, Inc.
Eleison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Eleison Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug candidates for orphan oncology indications. Its portfolio of drug candidates consists of glufosfamide, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). The company was founded by Edwin J. Thomas on October 14, 2009 and is headquartered in Princeton, NJ. | Health Technology |
- Borsa valori
- Insiders
- Matthew Parris